RT Journal Article SR Electronic T1 Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1205 OP 1211 DO 10.2967/jnumed.119.236000 VO 61 IS 8 A1 Rousseau, Caroline A1 Goldenberg, David M. A1 Colombié, Mathilde A1 Sébille, Jean-Charles A1 Meingan, Philippe A1 Ferrer, Ludovic A1 Baumgartner, Pierre A1 Cerato, Evelyne A1 Masson, Damien A1 Campone, Mario A1 Rauscher, Aurore A1 Fleury, Vincent A1 Labbe, Catherine A1 Chauvet, Alain Faivre A1 Fresnel, Jean-Sebastien A1 Toquet, Claire A1 Barbet, Jacques A1 Sharkey, Robert M. A1 Campion, Loic A1 Kraeber-Bodéré, Françoise YR 2020 UL http://jnm.snmjournals.org/content/61/8/1205.abstract AB This prospective study evaluated the imaging performance of a novel pretargeting immunologic PET (immuno-PET) method in patients with human epidermal growth factor receptor 2 (HER2)–negative, carcinoembryonic antigen (CEA)–positive metastatic breast cancer, compared with CT, bone MRI, and 18F-FDG PET. Methods: Twenty-three patients underwent whole-body immuno-PET after injection of 150 MBq of 68Ga-IMP288, a histamine-succinyl-glycine peptide given after initial targeting of a trivalent anti-CEA, bispecific, antipeptide antibody. The gold standards were histology and imaging follow-up. Tumor SUVs (SUVmax and SUVmean) were measured, and tumor burden was analyzed using total tumor volume and total lesion activity. Results: The total lesion sensitivity of immuno-PET and 18F-FDG PET were 94.7% (1,116/1,178) and 89.6% (1,056/1,178), respectively. Immuno-PET had a somewhat higher sensitivity than CT or 18F-FDG PET in lymph nodes (92.4% vs. 69.7% and 89.4%, respectively) and liver metastases (97.3% vs. 92.1% and 94.8%, respectively), whereas sensitivity was lower for lung metastases (48.3% vs. 100% and 75.9%, respectively). Immuno-PET showed higher sensitivity than MRI or 18F-FDG PET for bone lesions (95.8% vs. 90.7% and 89.3%, respectively). In contrast to 18F-FDG PET, immuno-PET disclosed brain metastases. Despite equivalent tumor SUVmax, SUVmean, and total tumor volume, total lesion activity was significantly higher with immuno-PET than with 18F-FDG PET (P = 0.009). Conclusion: Immuno-PET using anti-CEA/anti-IMP288 bispecific antibody, followed by 68Ga-IMP288, is a potentially sensitive theranostic imaging method for HER2-negative, CEA-positive metastatic breast cancer patients and warrants further research.